RESUMO
Administration of long-acting injectable suspensions is an increasingly common approach to increasing patient compliance and improving therapeutic efficacy through less frequent dosing. While several long-acting suspensions have recently been marketed, parameters modulating drug absorption from suspension-based formulations are not well understood. Further, methods for predicting clinical pharmacokinetic data from preclinical studies are not well established. Together, these limitations hamper compound selection, formulation design and formulation selection through heavy reliance on iterative optimization in preclinical and clinical studies. This article identifies key parameters influencing absorption from suspension-based formulations through compilation and analysis of preclinical and clinical pharmacokinetic data of seven compounds marketed as suspensions; achievable margins for predicting the clinical dose and input rate from preclinical studies as a function of the preclinical species, the clinical injection location and the intended therapeutic duration were also established.
Assuntos
Suspensões , Humanos , Estudos Retrospectivos , InjeçõesRESUMO
Amorphous solid dispersions (ASDs) have been widely utilized to enhance the bioavailability of pharmaceutical drugs with poor aqueous solubility. The role of various excipients on the amorphous drug to crystalline form conversion in ASDs has been widely documented. However, there has been no published study to investigate the role of film coating material on the physical stability of an ASD based tablet formulation, to the best of our knowledge. Here we show that the film coating can potentially have a detrimental impact on the physical stability of spray dried intermediates (SDI) in tablet formulations. The impact of the film coating on the physical stability of SDI was found to be related to the film coat material composition, and an increase in the film coating thickness led to a reduction in the physical stability of SDI in tablets. Oral compressed tablets in which the film coat material was "mixed-in" with the formulation blend showed a similar or worse physical stability than film coated tablets, further underscoring the film coat material impact on physical stability, independent of the film coating process. This study demonstrates a need for careful consideration of the film coat material selection for ASD based pharmaceutical product development.
Assuntos
Química Farmacêutica , Cristalização , Comprimidos/química , Solubilidade , Composição de Medicamentos , Estabilidade de MedicamentosRESUMO
OBJECTIVES: To assess the role of intestinal lymphatic transport in the oral bioavailability and brain deposition of a highly lipophilic, centrally acting drug candidate (Org 49209) in comparison to cholesterol, a close structural analogue. METHODS: The intestinal lymphatic transport of Org 49209 and cholesterol was assessed in lymph-cannulated anaesthetised rats and total bioavailability evaluated in non-lymph-cannulated animals. Parallel groups were employed to examine the brain deposition of Org 49209 after intraduodenal and intraperitoneal administrations. KEY FINDINGS: The contribution of intestinal lymphatic transport to total bioavailability was similar for Org 49209 and cholesterol (approximately 40% of the absorbed dose). However, the oral bioavailability of Org 49209 was significantly (fourfold) lower than cholesterol. Brain deposition of Org 49209 was similar after intraduodenal and intraperitoneal administration. Systemic exposure, however, was higher after intraduodenal administration and brain-to-plasma ratios were therefore reduced. CONCLUSION: The oral bioavailability of Org 49209 was significantly lower than that of its structural analogue cholesterol; however, intestinal lymphatic transport played a similar role in oral bioavailability for both compounds. Brain to plasma ratios were lower after intraduodenal versus intraperitoneal administration, suggesting that drug association with intestinal lymph lipoproteins may limit central nervous system access for highly lipophilic drugs.
Assuntos
Encéfalo/metabolismo , Fármacos do Sistema Nervoso Central/farmacocinética , Colesterol/análogos & derivados , Colesterol/farmacocinética , Mucosa Intestinal/metabolismo , Linfa/metabolismo , Sistema Linfático/metabolismo , Noresteroides/farmacocinética , Administração Oral , Animais , Disponibilidade Biológica , Transporte Biológico , Fármacos do Sistema Nervoso Central/metabolismo , Colesterol/metabolismo , Absorção Intestinal , Lipoproteínas/metabolismo , Masculino , Estrutura Molecular , N-Metilaspartato/metabolismo , Noresteroides/metabolismo , Ratos Sprague-Dawley , Esquizofrenia/metabolismoRESUMO
Bioequivalence of drug formulations plays an important role in drug development. Recently, the Biopharmaceutical Classification System (BCS) has been implemented for the purpose of waiving bioequivalence studies on the basis of the solubility and gastrointestinal permeability of drug substance. Using the rationale of the BCS, it can be argued that biowaivers can, however, also be granted on the basis of standard pharmacokinetic data. If a drug exhibits dose-linear pharmacokinetics and a sufficiently fast dissolution profile, it can be concluded that this drug appears to pose no problem with respect to absorption. It should be noted that a change of an immediate-release tablet formulation can only lead to a deviating rate and/or extent of absorption when release of the drug from the formulation is altered. Logically, the dissolution profiles of the different formulations should be equal to guarantee bioequivalency. Thus, both BCS and the alternative linear pharmacokinetics approach require an evaluation of dissolution profiles. The justification of BCS is found in the permeability classification of the compound, while those of the linear pharmacokinetics lie in the apparent lack of a permeability problem. For example, in this context P-glycoprotein-transported drugs form an interesting class of compounds, which may be treated likewise when complying to the aforementioned requirements. Furthermore, poorly soluble compounds may be less troublesome than expected. It is shown that linear kinetics can be explained by the solubilising activity of, for example, bile salts. In this instance, linear pharmacokinetics shows that elevated doses do not appear to exhibit a limiting role on the dissolution. Hence, a change in formulation without any effect on the dissolution profile is not expected to cause a change in availability. It is clear that the formulations to be compared should not contain excipients that display an effect on (presystemic) drug metabolism.
Assuntos
Estrenos/farmacocinética , Furanos/farmacocinética , Cetoprofeno/farmacocinética , Naproxeno/farmacocinética , Noretindrona/análogos & derivados , Noretindrona/farmacocinética , Administração Oral , Animais , Bile/metabolismo , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Estrenos/administração & dosagem , Estrenos/sangue , Furanos/administração & dosagem , Furanos/sangue , Humanos , Cetoprofeno/administração & dosagem , Cetoprofeno/sangue , Naproxeno/administração & dosagem , Naproxeno/sangue , Noretindrona/administração & dosagem , Noretindrona/sangue , Solubilidade , Equivalência TerapêuticaRESUMO
Milling of agglomerates is one of the common unit operations during preparation of oral dosage forms like capsules and tablets. In literature the breakage of granules is mostly determined after single impact at an ideally formed granule or of single particles. In this paper the breakage behavior of agglomerates after milling with multiple impacts has been studied. It investigates the effects of the formulation and the influences of the mill settings. With respect to the formulation it has been found that both the size of the particles before granulation and the amount of binder used determine the breakage behavior. Both parameters have an influence on the strength of the granule to be milled, where initial particle size has the largest effect. A relation has been found between the strength of granules and the degree of size reduction. Regarding the mill settings, there are no mill parameters which influence the formation of fines independently. Formation of fines is always the result of the total degree of size reduction. It is not possible to achieve a large degree of size reduction without intensive fines formation. The results indicate that it is possible to achieve every desired average particle size. However, when formation of dust has to be reduced, multiple milling steps with separation of in-size particles is necessary.
Assuntos
Preparações Farmacêuticas/química , Tecnologia Farmacêutica/instrumentação , Tecnologia Farmacêutica/métodos , Administração Oral , Química Farmacêutica , Tamanho da Partícula , Preparações Farmacêuticas/administração & dosagemRESUMO
In this study the gastrointestinal absorption and P-glycoprotein (Pgp) efflux transport of heterocyclic drugs was investigated with the Caco-2 cell model. Based on the calculation of the physico-chemical properties a good oral absorption was predicted for all the drugs tested in this study which corresponded well with the measured Caco-2 permeabilities (Papp). Generally a high permeability of the tested heterocyclic drugs was measured being in agreement with earlier published human in vivo absorption data. Based on the transport data of domperidone and verapamil it was found that the Pgp efflux transporter was expressed in the Caco-2 cells. Many of the drugs tested were indicated to be potential Pgp efflux substrates. Since Pgp is expressed at the Blood Brain Barrier (BBB) as well, it was expected that CNS penetration will be impaired if a drug is a Pgp substrate. However, no correlation could be found between brain penetration in rats and the Pgp efflux ratio as measured with the Caco-2 cells. From the data it is concluded that Pgp efflux ratio's as determined in in vitro High Throughput Screening (HTS) tests, where the transport conditions are fixed (pH gradient, concentration, etc.), cannot routinely be used to predict a possible limited brain penetration.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Encéfalo/metabolismo , Permeabilidade da Membrana Celular , Compostos Heterocíclicos/farmacologia , Compostos Heterocíclicos/farmacocinética , Encéfalo/efeitos dos fármacos , Células CACO-2 , Permeabilidade da Membrana Celular/efeitos dos fármacos , Humanos , Transporte Proteico/efeitos dos fármacos , Transporte Proteico/fisiologiaRESUMO
PURPOSE: The purpose of this work was to study the relevant physicochemical properties for the absorption of steroids. METHODS: Various physicochemical properties of steroids were calculated (molecular weight, ClogP, static polar surface area [PSA], etc.). Within this series of steroids, different pharmacological groups were defined. Based on the outcome of this survey, steroids were selected for the Caco-2 permeability study. The apparent permeability coefficients (Papp) were related to the calculated and measured physicochemical properties. RESULTS: Between the defined groups of steroids, ClogP was the most discriminative descriptor. The steroids were well transported over the cell monolayers and the Papp was independent of the concentration and the transport direction. No relationship was found with the PSA; however, the Papp showed a weak inverse correlation with ClogP. CONCLUSIONS: The molecular descriptors and Papp values showed that all steroids are well transported. The small differences in the Papp values showed a weak inverse correlation with ClogP: the hydrophilic steroids (ClogP approximately 0-2) tend to diffuse faster over the cell monolayers compared with the more hydrophobic steroids (ClogP approximately 5). The relationship with ClogP suggests that partitioning of steroids between the biologic membrane and the surrounding aqueous phase is one of the main mechanisms for absorption.